- Home
- EDRY vs XLO Comparison
EDRY vs XLO Comparison
Compare EDRY & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDRY
- XLO
- Stock Information
- Founded
- EDRY 2018
- XLO 2016
- Country
- EDRY Greece
- XLO United States
- Employees
- EDRY N/A
- XLO N/A
- Industry
- EDRY Marine Transportation
- XLO Biotechnology: Pharmaceutical Preparations
- Sector
- EDRY Consumer Discretionary
- XLO Health Care
- Exchange
- EDRY Nasdaq
- XLO Nasdaq
- Market Cap
- EDRY 34.8M
- XLO 35.7M
- IPO Year
- EDRY N/A
- XLO 2021
- Fundamental
- Price
- EDRY $12.66
- XLO $0.82
- Analyst Decision
- EDRY
- XLO Buy
- Analyst Count
- EDRY 0
- XLO 2
- Target Price
- EDRY N/A
- XLO $3.00
- AVG Volume (30 Days)
- EDRY 6.8K
- XLO 453.9K
- Earning Date
- EDRY 11-18-2025
- XLO 11-06-2025
- Dividend Yield
- EDRY N/A
- XLO N/A
- EPS Growth
- EDRY N/A
- XLO N/A
- EPS
- EDRY N/A
- XLO N/A
- Revenue
- EDRY $49,707,775.00
- XLO $15,001,000.00
- Revenue This Year
- EDRY N/A
- XLO $519.70
- Revenue Next Year
- EDRY $28.45
- XLO $44.57
- P/E Ratio
- EDRY N/A
- XLO N/A
- Revenue Growth
- EDRY N/A
- XLO 536.45
- 52 Week Low
- EDRY $7.60
- XLO $0.62
- 52 Week High
- EDRY $20.79
- XLO $1.70
- Technical
- Relative Strength Index (RSI)
- EDRY 60.31
- XLO 63.99
- Support Level
- EDRY $12.29
- XLO $0.79
- Resistance Level
- EDRY $12.89
- XLO $0.91
- Average True Range (ATR)
- EDRY 0.68
- XLO 0.04
- MACD
- EDRY -0.05
- XLO 0.00
- Stochastic Oscillator
- EDRY 29.41
- XLO 54.12
About EDRY EuroDry Ltd.
EuroDry Ltd is a holding company. It is a provider of ocean-going transportation. The company owns and operates dry bulk carriers that transport bulk such as iron ore, coal, and grains, and minor bulks such as bauxite, phosphate, and fertilizers. It operates under one operating and one reportable segment, that of operating dry bulk vessels.
About XLO Xilio Therapeutics Inc.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).